EUVIMEDEUVIMED entdecken
Crossref

Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation

Yi Zheng, Ying Liu, Xinyu Zheng, Gary Tse iD, Gregory Y H Lip, Kang-Yin Chen, Tong Liu iD

Postgraduate Medical Journal · 2026

DOI: 10.1093/postmj/qgaf163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2026. Verfasst von Yi Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospi…. Hauptthemen laut MEDLINE: Rivaroxaban, Atrial Fibrillation, Myocardial Infarction, Factor Xa Inhibitors. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Construction Project, Tianjin Key Medical Discipline, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New-onset atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) is associated with higher risks of stroke and mortality. However, current guidelines lack specific antithrombotic recommendations for this population. This study aimed to explore the association between rivaroxaban and the prognosis of patients with AMI and new-onset AF.

Methods

This retrospective cohort study included patients with AMI and new-onset AF receiving dual antiplatelet therapy between August 2016 and June 2023 in Tianjin, China. New-onset AF (transient or nontransient) was defined as the first diagnosis of AF following AMI. The primary outcome was stroke.

Results

2477 patients were identified, including 141 rivaroxaban users and 2336 patients without oral anticoagulants (OAC). Over a median follow-up of 922 days, rivaroxaban users had a 5.7% lower risk of stroke than non-OAC users, although this was not statistically significant (19.9% vs. 25.6%; P = .152). Despite the suggestion of a protective trend, multivariable Cox regression showed that rivaroxaban use was not associated with a lower risk of stroke (hazard ratio, 0.77; 95% confidence interval, 0.52–1.13, P = .187). After propensity score matching, 155 transient (rivaroxaban: 42; non-OAC: 113) and 295 nontransient AF patients (rivaroxaban: 85; non-OAC: 210) were included. No significant association was observed between rivaroxaban and stroke, ischemic stroke, hemorrhagic stroke, all-cause mortality, cardiovascular mortality, bleeding, or major bleeding.

Conclusion

No significant association was observed between rivaroxaban and clinical outcomes in patients with AMI and new-onset AF. Given the small sample size and limited statistical power, the findings are exploratory and require further validation. Key messages What is already known on this topic: Evidence from previous studies indicates that acute myocardial infarction (AMI) patients with new-onset atrial fibrillation (AF) are associated with higher risks of ischemic stroke and mortality. However, the association between rivaroxaban and the prognosis of patients with AMI and new-onset AF remains uncertain. What this study adds: Among patients with AMI and new-onset AF receiving dual antiplatelet therapy, no significant differences were observed between rivaroxaban users and non-oral anticoagulant users in terms of the risks of stroke, ischemic stroke, hemorrhagic stroke, all-cause mortality, cardiovascular mortality, bleeding, or major bleeding. However, these results should be interpreted with caution due to the small sample size and limited statistical power of the study. How this study might affect research, practice or policy: Future prospective large-scale studies and randomized controlled trials are needed to further examine the role of rivaroxaban and other types of oral anticoagulants in patients with AMI and new-onset AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanAtrial FibrillationMyocardial InfarctionFactor Xa InhibitorsStrokeHumansMaleFemaleRetrospective StudiesAgedPrognosisMiddle AgedChinaPlatelet Aggregation InhibitorsRisk Factors

Stichwörter der Autor:innen

acute myocardial infractionbleedingmortalitynew-onset atrial fibrillationrivaroxabanstroke

Substanzen

RivaroxabanFactor Xa InhibitorsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi Distri…
  • School of Nursing and Health Sciences, Hong Kong Metropolitan University, 1 Sheung Shing Street, Quarry Hill, Kowloon, 999077, Hong Kong, China.
  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, 6 West Derby Street, L7 8TX, Liverpool, United Kingdom.
  • Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 7K, 9220, Aalborg, Denmark.

ORCID-Profile: Gary Tse, Tong Liu

Förderung

  • Construction Project
  • Tianjin Key Medical Discipline
  • National Natural Science Foundation of China

Zitieren

APA

Zheng, Y., Liu, Y., Zheng, X., Tse, G., Lip, G. Y. H., Chen, K. Y., & Liu, T. (2026). Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf163

Vancouver

Zheng Y, Liu Y, Zheng X, Tse G, Lip GYH, Chen KY, et al. Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation. Postgraduate Medical Journal. 2026. doi:10.1093/postmj/qgaf163

BibTeX
@article{Zheng2026,
  author = {Zheng, Yi and Liu, Ying and Zheng, Xinyu and Tse, Gary and Lip, Gregory Y H and Chen, Kang-Yin and Liu, Tong},
  title = {Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation},
  journal = {Postgraduate Medical Journal},
  year = {2026},
  doi = {10.1093/postmj/qgaf163}
}
Kostenlos starten →